AXSM - Axsome Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
26.01
+1.10 (+4.42%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close24.91
Open25.12
Bid0.00 x 1400
Ask0.00 x 800
Day's Range24.90 - 26.07
52 Week Range1.94 - 28.70
Volume399,150
Avg. Volume1,055,332
Market Cap895.228M
Beta (3Y Monthly)2.85
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire

    Axsome Therapeutics Appoints David Marek as Chief Commercial Officer

    Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the appointment of David Marek as Chief Commercial Officer, effective August 31, 2019. Mr. Marek joins Axsome from Amgen, where he was Vice President, and General Manager of Amgen’s Neuroscience business unit, and previously held executive positions at WebMD and at Saatchi & Saatchi Healthcare Advertising.

  • GlobeNewswire

    Axsome Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update

    Both STRIDE-1 Phase 3 trial in TRD and GEMINI Phase 3 trial in MDD for AXS-05 on track for readout of topline results in 2H 2019 MOMENTUM Phase 3 trial of AXS-07 in migraine on.

  • GlobeNewswire

    Axsome Therapeutics To Report Second Quarter 2019 Financial Results On August 8, 2019

    Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it will report its financial results for the second quarter of 2019 on Thursday, August 8, 2019 before the opening of the U.S. financial markets.

  • GlobeNewswire

    Axsome Therapeutics Amends Silicon Valley Bank Loan Agreement Increasing Financial Flexibility

    Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, announced that it has amended its existing $24 million term loan facility agreement led by Silicon Valley Bank (SVB). Axsome entered into the $24 million loan agreement in March 2019. The amendment extends the interest-only payment period by a minimum of six months to 18 months, which may be further extended to 24 months should the Company elect to draw down an additional $4 million that remains unfunded under the loan agreement.

  • GlobeNewswire

    Axsome Therapeutics Added to Russell 3000® and Russell 2000® Indexes

    Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, has been added to the Russell 3000® and Russell 2000® Indexes, as part of the annual Russell indexes reconstitution, which took place following the US market close on June 28, 2019. The Russell indexes are rebalanced each June in order to capture growing equities and market changes that occurred in the preceding year. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.

  • GlobeNewswire

    Axsome Therapeutics Initiates GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder

    Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, enrolled the first patient in its GEMINI (Glutamatergic and Monoaminergic Modulation in Depression) study, a Phase 3, randomized, double-blind, placebo-controlled trial of AXS-05 in the treatment of major depressive disorder (MDD). AXS-05 is a novel, oral, investigational NMDA receptor antagonist with multimodal activity.

  • GlobeNewswire

    Axsome Therapeutics Provides Update on Continued Progress at Annual Stockholders’ Meeting

    Placebo-controlled Phase 3 trial of AXS-05 in MDD on track to start in 2Q 2019 Topline results from both STRIDE-1 Phase 3 trial in TRD and planned placebo-controlled Phase 3.

  • GlobeNewswire

    Axsome Therapeutics To Present Data From ASCEND Phase 2 Trial Of AXS-05 In Major Depressive Disorder At The 2019 American Society For Clinical Psychopharmacology Annual Meeting

    NEW YORK, May 21, 2019 -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous.

  • GlobeNewswire

    Axsome Therapeutics Reports First Quarter 2019 Financial Results and Provides Business Update

    Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the first quarter ended March 31, 2019. “The first five months of 2019 have been highly productive at Axsome as we advanced our mission to develop innovative medicines for patients living with serious and difficult-to-treat CNS disorders. “We also received Breakthrough Therapy designation from the FDA for AXS-05 for the treatment of major depressive disorder, and recently announced, based on the Breakthrough Therapy meeting, an expedited clinical development plan for AXS-05 in depression which could result in a potential NDA filing for AXS-05 in 2020.

  • GlobeNewswire

    Axsome Therapeutics Announces Acceleration of MOMENTUM Phase 3 Trial of AXS-07 in Migraine

    Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the acceleration of the timeline for reporting topline results from the MOMENTUM Phase 3 trial of AXS-07 (MoSEIC™ meloxicam and rizatriptan), Axsome’s novel, oral, investigational medicine with distinct dual mechanisms of action for the acute treatment of migraine. The trial is being conducted pursuant to a U.S. Food and Drug Administration (FDA) Special Protocol Assessment (SPA).

  • GlobeNewswire

    Axsome Therapeutics Announces Expedited Development and Pivotal Status for AXS-05 in the Treatment of Major Depressive Disorder based on FDA Breakthrough Therapy Meeting

    Previously completed active-controlled ASCEND trial in MDD now considered as pivotal; sufficient with ongoing STRIDE-1 Phase 3 trial for NDA in MDD Target randomization for.

  • GlobeNewswire

    Axsome Therapeutics To Report First Quarter 2019 Financial Results On May 9, 2019

    Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it will report its financial results for the first quarter of 2019 on Thursday, May 9, 2019 before the opening of the U.S. financial markets.

  • GlobeNewswire

    Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in Phase 2 Trial in Smoking Cessation

    Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Duke University has completed its topline analysis of the Phase 2 trial of AXS-05 for smoking cessation treatment. The analysis showed that AXS-05 met the prespecified primary endpoint and significantly reduced daily smoking as compared to the active comparator bupropion. The trial was conducted at the Duke Center for Smoking Cessation under a research collaboration between Axsome and Duke University.

  • GlobeNewswire

    Axsome Therapeutics Receives FDA Breakthrough Therapy Designation for AXS-05 for the Treatment of Major Depressive Disorder

    Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for AXS-05 for the treatment of major depressive disorder (MDD). AXS-05 is a novel, oral, investigational NMDA receptor antagonist with multimodal activity.

  • GlobeNewswire

    Axsome Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

    Company to host conference call today at 8:00 AM Eastern NEW YORK, March 14, 2019 -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company.

  • GlobeNewswire

    Axsome Therapeutics Secures $24 Million Growth Capital Loan Facility Led by Silicon Valley Bank

    Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, has entered into a $24 million growth capital term loan facility with Silicon Valley Bank (SVB) and WestRiver Innovation Lending Fund. Axsome received $20 million at closing, and can draw the remaining $4 million tranche, at its option, subject to the achievement of positive results from the Company’s ongoing Phase 2 trial of AXS-12 in narcolepsy. “Together, these financings extend our cash runway well beyond the data readouts for our five ongoing clinical trials, in five different CNS indications, expected over the next several quarters.

  • GlobeNewswire

    Axsome Therapeutics to Report Fourth Quarter and Full Year 2018 Financial Results on March 14, 2019

    Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it will report its financial results for fiscal year 2018 on Thursday, March 14, 2019 before the opening of the U.S. financial markets. AXS-02 is being developed for osteoporosis, the pain of knee osteoarthritis, and chronic low back pain.

  • GlobeNewswire

    Axsome Therapeutics Initiates MOMENTUM Phase 3 Trial of AXS-07 in Migraine

    Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, enrolled the first patient in its MOMENTUM (Maximizing Outcomes in Treating Acute Migraine) study, a Phase 3, randomized, controlled trial assessing the efficacy and safety of AXS-07 (MoSEIC™ meloxicam and rizatriptan) in the acute treatment of migraine. MOMENTUM will enroll only patients with a history of inadequate response to prior migraine treatments.

  • GlobeNewswire

    Axsome Therapeutics Receives FDA Agreement under Special Protocol Assessment (SPA) for the MOMENTUM Phase 3 Trial of AXS-07 in Migraine

    Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, has reached agreement with the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for the design, endpoints, and statistical approach of the planned MOMENTUM (Maximizing Outcomes in Treating Acute Migraine) Phase 3 trial of AXS-07 (MoSEIC™ meloxicam and rizatriptan) in the acute treatment of migraine. MOMENTUM will enroll only patients with a history of inadequate response to prior migraine treatments.

  • GlobeNewswire

    Axsome Therapeutics Initiates Phase 2 Trial of AXS-12 in Narcolepsy

    Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, has initiated the CONCERT (Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment) study, a Phase 2, randomized, controlled trial of AXS-12 (reboxetine) in narcolepsy. AXS-12 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of narcolepsy. Topline results from the CONCERT trial are expected in the second quarter of 2019.

  • ACCESSWIRE

    Market Rally Extends to Biotech

    HENDERSON, NV / ACCESSWIRE / January 9, 2019 / Markets are rallying in first full market week of 2019 and the biotech sector is responding as many oversold small caps are starting to rebound. We've found ...

  • ACCESSWIRE

    This Stock Generated 25X Returns In Just Five Years: Could BTCY Be At The Same Crossroads?

    The move to get patients out of doctors offices and hospitals quickly using virtual care and remote monitoring is underway. Technology is enabling the switch, and few subsectors have benefitted more than remote cardiac care. Companies like Biotelemetry (BEAT) have grown by leaps and bounds in the last few years as their proprietary remote cardiac monitoring devices have gained traction.

  • ACCESSWIRE

    The Next Big Biotech Breakout

    HENDERSON, NV / ACCESSWIRE / January 8, 2019 / Celgene's major deal with Bristol-Myers Squibb seems to have woken up the sleeping giant that is the biotech market. Axsome announced positive trial data ...

  • GlobeNewswire

    Axsome Therapeutics Raises $23.3 Million Under Existing ATM Facility

    Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, announced that today it raised approximately $23.3 million through the sale of 2,881,066 shares under its existing at-the-market (ATM) facility with Leerink Partners LLC. Axsome intends to use the proceeds from this offering to continue to fund the ongoing clinical development of its late stage product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates.

  • ACCESSWIRE

    4 Healthcare Stocks Making Moves On Monday (1/7/19)

    CORAL GABLES, FL / ACCESSWIRE / January 7, 2019 / The healthcare industry is predicated on the notion that as diseases become more advanced and difficult to treat, companies responsible for creating treatment options will rise to the occasion to assist patients suffering from said ailments. Given that the world's population is consistently increasing, and resources are diminishing, access to healthcare presents a dire need for consumers on a global scale. As healthcare companies work to develop new methods for bettering the care provided to their patients, the industry, in its entirety, will unite to meet the demands and needs of consumers in the space looking for qualitative healthcare.